Prior studies have shown that plasma markers of neuroaxonal damage—NFL and glial fibrillary acidic protein (GFAP)—are elevated early in the MS disease course and show potential use for tracking disease activity and response to treatment.2, 3. This evidence concerns the gene NEFL and myeloid sarcoma.